Business Standard

Gland Pharma enters into agreement to acquire Cenexi; stock slips 5%

The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones, the company said

Gland Pharma
Premium

SI Reporter Mumbai
Shares of Gland Pharma slipped 5 per cent to Rs 1,787.55 on the BSE in Wednesday's intra-day trade after the company entered into a Put Option Agreement to acquire 100 per cent of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million).

Gland Pharma will acquire Cenexi Group through its wholly owned subsidiary Gland Pharma International PTE. Ltd, Singapore.

Cenexi is primarily engaged in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill-finished drug, including capabilities on oncology and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 30 2022 | 11:16 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com